ARGX vs REGN
argenx SE and Regeneron Pharmaceuticals, both Healthcare
Regeneron Pharmaceuticals is the larger company at $64B against $56B. On trailing earnings REGN is the cheaper of the two at a P/E of 18.4 against 42.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year REGN returned +25% against +12% for ARGX. The RyuScore puts REGN ahead, 70 against 11 out of 100.
| Figure | ARGX | REGN |
|---|---|---|
| Last close | $825 | $746 |
| Market cap | $56B | $64B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 42.2 | 18.4 |
| 1-year return | +12% | +25% |
| 5-year return | +156% | +18% |
| RyuScoresector-relative, 1–10 | 11/100 | 70/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
argenx SE
Revenue of $2.5B in H2 2025, net income $877M.
Regeneron Pharmaceuticals
Revenue of $4.3B in Q2 2026, net income $1.3B. Its largest reported line is Share Of Profit Losses, 50% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.